About Inhibrx
Inhibrx is a publicly listed company based in Solana Beach (United States) founded in 2009, and was acquired by Sanofi in January 2024. It operates as an antibody-based immunotherapeutics are developed for cancer and infectious diseases. Inhibrx has raised $468.55 million across 11 funding rounds from investors including Sanofi, HHS and Oxford Finance. The company has 161 employees. Inhibrx offers products and services including Ozekibart (INBRX-109) and INBRX-106. Its focus areas include Life Sciences, Immunotherapy, Antibody and Immunomodulatory. Its legal entity is INHIBRX, INC. Its competitors include Moderna, Merck, Roivant Sciences, BeiGene and AbbVie and 5 more; 3 of its 10 listed competitors have raised funding.
Company details
Antibody-based immunotherapeutics for cancer and infectious diseases. it has proprietary platforms that enable fit-for-function bio-therapeutics that optimally interface with the biology of each target antigen, focus immune activation, and mediate enhanced signaling. Its product pipeline includes INBRX-109 an engineered tetravalent sdAb-based therapeutic candidate to induce tumor selective programmed cell death, and INBRX-106 is a hexavalent sdAb-based therapeutic candidate targeting OX40 to treat locally advanced or metastatic solid tumors.
- Headquarters Solana Beach, United States
- Employees 161
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website inhibrx.com
- Social LinkedIn X Facebook
- Acquired by Sanofi (Jan 2024)
- Legal Name Inhibrx Biosciences, Inc.
- Annual Revenue$1.3 M (USD)550as on Dec 31, 2025
- Net Profit-$140.06 M (USD)-108.3as on Dec 31, 2025
- EBITDA-$132.54 M (USD)59.73as on Dec 31, 2025
- Total Equity Funding$468.55M (USD)
in 11 rounds
- Latest Funding Round$200M (USD), Post-IPO
Sep 2023
- InvestorsSanofi
& 3 more
- Employee Count161
- Acquired bySanofi
(Jan 2024)
Products & Services of Inhibrx
Inhibrx offers a comprehensive portfolio of products and services, including Ozekibart (INBRX-109) and INBRX-106.
Novel biologic for treating life-threatening conditions via protein engineering.
Innovative therapeutic in pipeline for life-threatening disease management.
Funding Insights of Inhibrx
Inhibrx has successfully raised a total of $468.55M across 11 strategic funding rounds. The most recent funding activity was a Post-IPO round of $200 million completed in September 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $468.55M
- Total Rounds 11
- Last Round Post-IPO — $200M
- First Round $20M
(Apr 2015)
- Investors Count 3
Latest 10 of 11 funding rounds of Inhibrx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2023 | $200M | Post-IPO | – | – | – |
| Feb 2021 | $279,433 | Grant | – | – | |
| Apr 2020 | $15M | Series D | – | – | – |
| Apr 2020 | $10M | Debt – Conventional | – | – | |
| May 2019 | $40M | Series D | – | Viking Global Investors | – |
| Sep 2018 | $264,155 | Grant | – | – | |
| May 2018 | $3.55M | Series D | – | – | – |
| Apr 2018 | $410M | Series D | – | – | – |
| Aug 2017 | $224,402 | Grant | – | – | |
| Feb 2017 | $1.22M | Grant | – | – |
4 investors in total: 4 institutional.
Investors in Inhibrx
Inhibrx has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Sanofi, HHS and Oxford Finance.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture debt firm focused on the life sciences sector | 2002 | oxfordfinance.com | Alexandria, United States | |
Private investment firm focused on multiple sectors | – | vikingglobal.com | Greenwich, United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - | |
Pharmaceutical and nutraceutical products are developed across seven therapeutic areas. | 1973 | sanofi.com | Paris, France |
Investor details for Inhibrx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Inhibrx
34 people are tracked at Inhibrx (21 in leadership, 10 in board & advisors, 3 in team); the tracked headcount is 161.
| Name | Role | Group |
|---|---|---|
Brian Lobo | VP, Formulation Development & Drug Product Manufacturing | Leadership |
Melissa Masterson | VP, Value, Access & Distribution | Leadership |
Erin Babcock | Senior Clinical Director | Leadership |
David Kao | VP, Regulatory Affairs | Leadership |
Ashraf Amanullah | EVP & Chief Technical Operations Officer | Leadership |
Dean Wagner | Executive Director, Medical Affairs And Business Development | Leadership |
Cary Opel | Senior Director, Cell Culture Process Development And Manufacturing | Leadership |
Matt Schenauer | Senior Director ADQC | Leadership |
Miranda Fox | Associate Director Clinical Operations | Leadership |
Sandipan Sinha | Senior Director | Leadership |
Robert Boothroyd | VP, Medical Affairs & Business Development | Leadership |
Dana Ebbets-Reed | VP, Quality Assurance | Leadership |
Kelly Deck | EVP & CFO | Leadership |
Mark P. Lappe | Founder & CEO | Leadership |
Ann Vento | IT Business Partner, Gxp Systems | Leadership |
Darren Brown | VP, Analytical Development & Quality Control | Leadership |
Bonne Adams | VP Operations | Leadership |
Deanna W. | Director, Biomarker Operations And Strategy | Leadership |
Delia Alvarez | Executive Director Clinical Operations | Leadership |
Susan W. | Senior Director Regulatory Affairs | Leadership |
14 more people are available in the full profile.
Complete people profiles for Inhibrx
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Inhibrx
Inhibrx is a publicly listed company on the NASDAQ with ticker symbol INBX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date19 Aug 2020
- Listed onNASDAQ: INBX
- Listed entityInhibrx Biosciences, Inc.
- Exchange sectorHealth technology
- ISINUS45720N1037
- Share price$87.08 (-3.81% on the day) · 2026-10-13
- Market capitalisation$1.28B
- EPS (diluted, trailing year)$-8.88
- Volume (last session)271,317
Financials of Inhibrx
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $1.3M | -$140.1M | -$132.5M |
| 2024 | $200,000 | $1.69B | -$329.2M |
| 2023 | $1.8M | -$241.4M | -$218.0M |
| 2022 | $2.2M | -$145.2M | -$127.9M |
Detailed financial statements for Inhibrx
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Inhibrx
5 dated milestones of Inhibrx across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Inhibrx is founded.
- Funding First funding round of $20.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $200.0M.
- Exit Acquired by Sanofi.
Competitors of Inhibrx
Inhibrx has 10 listed competitors in our database, 3 of them funded. They include Moderna, Merck, Roivant Sciences, BeiGene and AbbVie, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| merck.com | 1891 | Kenilworth, United Kingdom | – | 781 | Pharmaceutical products are manufactured and marketed worldwide. | |
| roivant.com | 2014 | New York, United States | $1.3B | 662 | Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| abbvie.com | 2012 | Chicago, United States | – | 8,667 | Biopharmaceutical research and drug development are conducted globally by AbbVie. | |
| gilead.com | 1987 | Foster, United States | – | 4,267 | Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | |
| lilly.com | 1876 | United States | – | 39,000 | Traditional pharmaceutical medicines are developed for multiple health fields. | |
| incyte.com | 1991 | Wilmington, United States | – | 1,387 | Small molecules are developed for cancer and skin disease treatments. | |
| vrtx.com | 1989 | United States | – | 5,400 | Developer of drugs for the treatment of multiple disorders | |
| morphosys.com | 1992 | Planegg, Germany | – | 732 | Therapeutic antibodies for cancer and other diseases are developed. |
Detailed competitors of Inhibrx
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Inhibrx
The website of Inhibrx (inhibrx.com) receives about 4.1K visits a month.
- Monthly visits4.1K
▼ 24.7% vs previous month
Top companies in Immunology & Cancer Therapeutics
10 companies that operate in the same segment as Inhibrx (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 213.52 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Inhibrx
Complete news archive for Inhibrx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Inhibrx
Inhibrx was founded in 2009 and raised its 1st funding round 6 years after it was founded.
Inhibrx is headquartered in Solana Beach, United States. It is registered at Solana Beach, California, United States.
Inhibrx is a funded company, having raised a total of $468.55M across 11 funding rounds to date. The company's 1st funding round was a Grant of $1.22M, raised on Apr 2015.
Inhibrx has 161 employees.
Annual revenue of Inhibrx is $1.3M as on Dec 31, 2025.
Antibody-based immunotherapeutics for cancer and infectious diseases. it has proprietary platforms that enable fit-for-function bio-therapeutics that optimally interface with the biology of each target antigen, focus immune activation, and mediate enhanced signaling. Its product pipeline includes INBRX-109 an engineered tetravalent sdAb-based therapeutic candidate to induce tumor selective programmed cell death, and INBRX-106 is a hexavalent sdAb-based therapeutic candidate targeting OX40 to treat locally advanced or metastatic solid tumors.
Inhibrx's top competitors include Merck, Moderna and Roivant Sciences.
Inhibrx offers Ozekibart (INBRX-109) and INBRX-106.
Yes, Inhibrx is publicly traded on NASDAQ under the ticker symbol INBX.
Inhibrx has 4 investors. Key investors include Sanofi, HHS, Oxford Finance, and Viking Global Investors.
Inhibrx operates through Inhibrx, Inc..
Yes. Inhibrx was acquired by Sanofi in January 2024.